Concepedia

Author

Claudia A.M. Stege

Vrije Universiteit AmsterdamORCID

Also Known As

C. A. Stege, C. Stege, C.A.M. Stege, Claudia A M Stege, Claudia A. M. Stege, Claudia A.M. Stege, Claudia Stege, Klein, Saskia

46

Publications

581

Citations

13

H-Index

29

Concepts

All Affiliations

Vrije Universiteit AmsterdamAmsterdam University Medical CentersAlbert Schweitzer ZiekenhuisErasmus MC Cancer InstituteMeander Medisch Centrum
CA

About

Claudia A.M. Stege is an author at Vrije Universiteit Amsterdam specializing in medicine, health sciences, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

2

2

78

2

Medicine

2

2

42

3

Engineering

1

1

65

4

Public Health

1

1

29

5

Family Medicine

1

1

29

Claudia A.M. Stege

×

13

Publications

319

Citations

11

H-Index

YearCitations

18F-FDG PET/CT compared to conventional imaging modalities in pediatric primary bone tumors

Kevin London, Claudia A.M. Stege, Siobhan Cross,

Pediatric Radiology

2011

65

Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study

Claudia A.M. Stege, Kazem Nasserinejad, Ellen van der Spek,

Journal of Clinical Oncology

2021

60

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

Lene Kongsgaard Nielsen, Claudia A.M. Stege, Birgit I. Lissenberg‐Witte,

Haematologica

2019

32

Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma

Hira Mian, Shakira J. Grant, Monika Engelhardt,

Journal of Geriatric Oncology

2020

29

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Lina van der Straten, Claudia A.M. Stege, Sabina Kersting,

Blood

2023

23

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study

Claudia A.M. Stege, Kazem Nasserinejad, Mark‐David Levin,

Blood

2018

20

Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study

Claudia A.M. Stege, Kazem Nasserinejad, Mark‐David Levin,

Blood

2018

15

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Claudia A.M. Stege, Kazem Nasserinejad, Ellen van der Spek,

Blood

2019

15

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma

Marina Zajec, Kristine A. Frerichs, Martijn M. VanDuijn,

HemaSphere

2020

13

Improving the identification of frail elderly newly diagnosed multiple myeloma patients

Claudia A.M. Stege, Kazem Nasserinejad, Saskia K. Klein,

Leukemia

2021

13

Page 1